Main Article Content

Abstract

Diabetes Mellitus (DM) remains a prominent global health concern, involving intricate disruptions in insulin secretion, insulin action, or both. Over the past century, evolving research and clinical insights have reshaped understanding of this disease from its historical recognition in ancient medical texts to contemporary approaches informed by genomics and precision medicine. In Type 1 Diabetes Mellitus (T1DM), autoimmune processes target pancreatic beta cells, resulting in absolute insulin deficiency, whereas Type 2 Diabetes Mellitus (T2DM) arises from insulin resistance and a progressive loss of beta-cell function. Advances in diagnostic methodologies, including continuous glucose monitoring, enhance the identification of glycemic variability, while comprehensive management strategies emphasize the synergy of pharmacologic agents, such as metformin and incretin-based therapies, with structured lifestyle interventions. However, persistent challenges remain: chronic hyperglycemia predisposes individuals to a host of microvascular and macrovascular complications, posing a substantial clinical and economic burden. Emerging therapeutic frontiers ranging from islet cell transplantation to CRISPR-mediated gene editing hold promise for transformative outcomes. Nonetheless, socioeconomic and cultural barriers continue to drive global disparities in access to optimal care. Future efforts must integrate innovative technologies, personalized treatment paradigms, and public health initiatives to address this pervasive metabolic disorder. By synthesizing cutting-edge scientific discoveries with patient-centered care, clinicians and researchers can work collaboratively to mitigate the escalating impact of diabetes on both individual lives and healthcare systems worldwide.

Keywords

Diabetes Mellitus Insulin Resistance Continuous Glucose Monitoring Precision Medicine Chronic Complications

Article Details

How to Cite
A Jayasree, Mahendar Uduthala, Narsanna Jeeru, Jeevan Kumar Manikonda, & Nishant Tiwari. (2025). Comprehensive Review of Diabetes Mellitus: Current Perspectives, Challenges, and Emerging Frontiers. International Journal of Research in Pharmacology & Pharmacotherapeutics, 14(1), 67-76. Retrieved from https://ijrpp.com/ijrpp/article/view/617

References

  1. 1. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–281.
  2. 2. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018 Feb;14(2):88–98.
  3. 3. Ahmed AM. History of diabetes mellitus. Saudi Med J. 2002 Apr;23(4):373–378.
  4. 4. Langerhans P. Contributions to the microscopic anatomy of the pancreas. Berlin: Gustav Lange; 1869. p. 21–70.
  5. 5. Van Belle TL, Coppieters KT, Von Herrath MG. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev. 2011 Jan;91(1):79–118.
  6. 6. American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes 2019. Diabetes Care. 2019 Jan;42(Suppl 1):S13–S28.
  7. 7. Metzger BE, Coustan DR. Summary and Recommendations of the Fourth International Workshop Conference on Gestational Diabetes Mellitus. Diabetes Care. 1998 Aug;21(2):B161–B167.
  8. 8. Fajans SS, Bell GI. MODY: History, genetics, pathophysiology, and clinical decision making. Diabetes Care. 2011 Aug;34(8):1878–1884.
  9. 9. Steiner DF. The proinsulin C-peptide a multirole model. Exp Diabesity Res. 2004;5(1):7–14.
  10. 10. DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care. 2009 Nov;32(11):177–182.
  11. 11. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006 Dec;444(7121):860–867.
  12. 12. Matsuda M, DeFronzo RA. Glass half empty or half full? The challenges of identifying the etiology of type 2 diabetes mellitus. Curr Diab Rep. 2012 Jun;12(3):369–381.
  13. 13. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006 Mar;3(3):153–165.
  14. 14. Flannick J, Johansson S, Njølstad PR. Common and rare forms of diabetes mellitus: towards a continuum of diabetes subtypes. Nat Rev Endocrinol. 2016 Nov;12(7):394–406.
  15. 15. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006 Dec;444(7121):840–846.
  16. 16. Popkin BM, Adair LS, Ng SW. Now and then: The global nutrition transition. J Nutr. 2012 Jan;142(1):207–211.
  17. 17. Whiting DR, Guariguata L, Weil C, Shaw J. IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011 Dec;94(3):311–321.
  18. 18. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. Geneva: World Health Organization; 2006.
  19. 19. Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019 Aug;42(8):1593–1603.
  20. 20. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001 May;344(18):1343–1350.
  21. 21. Colberg SR, Sigal RJ, Yardley JE, Riddell MC, Dunstan DW, Dempsey PC, et al. Physical activity/exercise and diabetes: A position statement of the American Diabetes Association. Diabetes Care. 2016 Nov;39(11):2065–2079.
  22. 22. Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009 Oct;361(18):1736–1747.
  23. 23. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016 Nov;375(19):1834–1844.
  24. 24. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015 Nov;373(22):2117–2128.
  25. 25. Chiang JL, Kirkman MS, Laffel LM, Peters AL. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care. 2014 Jul;37(7):2034–2054.
  26. 26. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000 Jul;343(4):230–238.
  27. 27. Wong TY, Sun J, Kawasaki R, Ruamviboonsuk P, Gupta N, Lansingh VC, et al. Guidelines on diabetic eye care. Ophthalmology. 2018 Oct;125(10):1608–1622.
  28. 28. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001 Sep;345(12):861–869.
  29. 29. Callaghan BC, Cheng HT, Stables CL, Smith AL, Feldman EL. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol. 2012 Jun;11(6):521–534.
  30. 30. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. JAMA. 1979 May;241(19):2035–2038.
  31. 31. Heinemann L, Freckmann G. Continuous glucose monitoring in clinical practice. Lancet Diabetes Endocrinol. 2015 Sep;3(9):660–662.
  32. 32. Thabit H, Leelarathna L, Caldwell K, Tauschmann M, Allen JM, Kaya A, et al. Accuracy of a wearable continuous glucose monitoring system during exercise in type 1 diabetes. Diabetes Obes Metab. 2018 May;20(5):1093–1099.
  33. 33. Lee PA, Greenfield G, Pappas Y. Telemedicine as a means of delivering clinical care and diabetes self-management education to people with type 2 diabetes: A mixed-methods systematic review. J Clin Med. 2018 May;7(5):106.
  34. 34. Arambepola C, Farmer A, Perera R, Kinmonth AL, McCloughan L, Deakin T, et al. Self-monitoring of blood glucose in type 2 diabetes: a meta-analysis. Diabetologia. 2008 Aug;51(6):1110–1112.
  35. 35. Zhou K, Donnelly LA, Morris AD, Franks PW, Jennison C, Palmer CN, et al. Clinical and genetic determinants of progression of type 2 diabetes: A DIRECT study. Diabetes Care. 2014 Apr;37(4):1126–1132.
  36. 36. Tilg H, Moschen AR. Microbiota and diabetes: An evolving relationship. Gut. 2014 Sep;63(9):1513–1521.
  37. 37. Zeevi D, Korem T, Zmora N, Israeli D, Rothschild D, Weinberger A, et al. Personalized nutrition by prediction of glycemic responses. Cell. 2015 Nov;163(5):1079–1094.
  38. 38. Contreras I, Vehi J. Artificial intelligence for diabetes management and decision support: literature review. J Med Internet Res. 2018 May;20(5):e10775.
  39. 39. Chan JC, Zhang Y, Ning G. Diabetes in China: A societal solution for a personal challenge. Lancet Diabetes Endocrinol. 2014 Dec;2(12):969–979.
  40. 40. Mohan V, Deepa M, Farooq S, Datta M, Deepa R. Secular trends in the prevalence of diabetes and impaired glucose tolerance in urban South India The Chennai Urban Rural Epidemiology Study (CURES-17). Diabetologia. 2006 Jun;49(6):1175–1178.
  41. 41. Seidell JC, Halberstadt J. The global burden of obesity and the challenges of prevention. Ann Nutr Metab. 2015 Feb;66(Suppl 2):7–12.
  42. 42. Fisher L, Gonzalez JS, Polonsky WH. The confusing tale of depression and distress in patients with diabetes: A call for greater clarity and precision. Diabet Med. 2014 Jul;31(7):764–772.
  43. 43. Trief PM, Sandberg JG, Ploutz-Snyder R, Brittain R, Cibula D, Scisney-Matlock M, et al. Promoting couples collaboration in type 2 diabetes: The diabetes support project pilot data. Fam Syst Health. 2011 Jun;29(3):253–261.
  44. 44. Bhalerao MS, Bolshete PM, Swar BD, Bangera TA, Kolhe V, Tambe MJ, et al. Use of and satisfaction with complementary and alternative medicine in four chronic diseases: A cross-sectional study from India. Natl Med J India. 2013 Mar;26(2):75–78.
  45. 45. Jhala US, Mirmira RG. Regenerative medicine strategies for diabetes. J Clin Invest. 2021 Jan;131(1):e142246.